Inflammatory bowel disease (IBD) is a chronic inflammatory condition of the digestive tract with an uncertain etiology. At present, treatment of IBD is limited to 5-aminosalicylates, corticosteroids, and immunosuppressants, including azathioprine and 6-mercaptopurine. Because specific and curative treatments with acceptable toxicity and side effect profiles are lacking, there remains a demand for the development of effective therapeutic approaches. Of significant importance to the present application are our findings from previous studies, which demonstrated that bacterial products, such as fMLP and MDP, could be transported by the intestinal epithelial oligopeptide transporter, PepT1. Once taken up into the cytosol, these small bacterial peptides initiate an inflammatory response. These bacterial peptides can also interact directly with immune cells. Since immune cells, including macrophages, also express PepT1, they have the capacity to take up small bacterial peptides, which can then interact with the NBS- LRR family of intracellular receptors (e.g., NOD2) that mediate intracellular recognition of microbes and their products. Thus, together with the inflammatory response initiated at the epithelial level, these small bacterial peptides in immune system cells may lead to an inflammatory cascade that results in tissue damage. Our overall hypothesis is that PepT1 plays a critical role in regulating the immune response by serving as a gateway for bacterial products. The initial aim of this proposal is to investigate the induction of PepT1 expression in colonic epithelial cells. Secondly, we will investigate the role of immune cell-expressed PepT1 in intestinal inflammation using chimeric mice. Finally, PepT1 will be used to target the anti-inflammatory tripeptide, KPV, to inflamed colonic epithelial and immune cells. The project will involve a variety of biochemical and molecular approaches at both the in vitro and in vivo level. The proposed study will generate new insights that will be key to the design and development of therapeutic strategies to ameliorate intestinal inflammatory conditions, including IBD. More than one million adults and children in the United States suffer from IBD. New therapeutic strategies based on a better understanding of the pathogenesis of IBD will improve the clinical care of patients with this disorder

Public Health Relevance

Even though major advances have been made in the past decade with respect to understanding the genetics, environmental and immune dysregulation in IBD, the etiopathogenesis of IBD is poorly understood. It is envisaged that this investigation will define the molecular mechanisms underlying the functional role of hPepT1 in intestinal inflammation and initiate therapeutic strategies to ameliorate intestinal inflammatory conditions including IBD.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
High Priority, Short Term Project Award (R56)
Project #
2R56DK061941-06A2
Application #
7839501
Study Section
Clinical and Integrative Gastrointestinal Pathobiology Study Section (CIGP)
Program Officer
Carrington, Jill L
Project Start
2003-01-01
Project End
2011-06-30
Budget Start
2009-07-01
Budget End
2011-06-30
Support Year
6
Fiscal Year
2009
Total Cost
$381,175
Indirect Cost
Name
Emory University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
066469933
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Ingersoll, Sarah A; Ayyadurai, Saravanan; Charania, Moiz A et al. (2012) The role and pathophysiological relevance of membrane transporter PepT1 in intestinal inflammation and inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 302:G484-92
Dalmasso, Guillaume; Nguyen, Hang Thi Thu; Yan, Yutao et al. (2011) MicroRNA-92b regulates expression of the oligopeptide transporter PepT1 in intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol 300:G52-9
Dalmasso, Guillaume; Nguyen, Hang Thi Thu; Ingersoll, Sarah A et al. (2011) The PepT1-NOD2 signaling pathway aggravates induced colitis in mice. Gastroenterology 141:1334-45
Dalmasso, Guillaume; Nguyen, Hang Thi Thu; Yan, Yutao et al. (2010) MicroRNAs determine human intestinal epithelial cell fate. Differentiation 80:147-54
Laroui, Hamed; Dalmasso, Guillaume; Nguyen, Hang Thi Thu et al. (2010) Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model. Gastroenterology 138:843-53.e1-2
Wilson, D Scott; Dalmasso, Guillaume; Wang, Lixin et al. (2010) Orally delivered thioketal nanoparticles loaded with TNF-*-siRNA target inflammation and inhibit gene expression in the intestines. Nat Mater 9:923-8
Dalmasso, Guillaume; Nguyen, Hang Thi Thu; Charrier-Hisamuddin, Laetitia et al. (2010) PepT1 mediates transport of the proinflammatory bacterial tripeptide L-Ala-{gamma}-D-Glu-meso-DAP in intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol 299:G687-96